Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gleason score

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Gleason score. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-000490-36 Sponsor Protocol Number: CHUBX2016/38 Start Date*: 2018-02-19
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude monocentrique, exploratoire, comparant la TEP/TDM au 68Ga-RM2 à la TEP/TDM au 68Ga-PSMA-617 chez des patients atteints de cancers de la prostate de différents risques métastatiques, candidats...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002355-40 Sponsor Protocol Number: SPCG 12 Start Date*: 2005-08-23
    Sponsor Name:Scandinavian prostate cancer group
    Full Title: An open randomized phase III trial of six cycles of docetaxel versus surveillance after radical prostatectomy in prostate cancer patients with high grade pT3 or margin positive pT2
    Medical condition: Men, 18-70 years old, who have had radical prostatectomy due to prostate cancer and with a high grade pT3 or margin positive pT2 tumour may be candidates for the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Ongoing) FI (Completed) DK (Completed) IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004694-41 Sponsor Protocol Number: PRX302-2-08 Start Date*: 2017-02-03
    Sponsor Name:Sophiris Bio Corp. 1258 Prospect Street La Jolla, CA 92037 USA
    Full Title: A Multi-Centre, Open Label, Phase IIb Study, Evaluating the Safety, Tolerability and Efficacy of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004872 10036966 Prostatic neoplasms and hypertrophy HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004874-96 Sponsor Protocol Number: HL/IDP/PTS/001 Start Date*: 2005-08-17
    Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust
    Full Title: Protocol: HL/IDP/PTS/001 Tumour Profiling In An Open-Labelled, 2-Arm Study Investigating The Tolerability And Efficacy Of Taxotere In Patients With High Risk Prostate Cancer
    Medical condition: Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-002511-99 Sponsor Protocol Number: IOV-PR-CH-PET-1-2013 Start Date*: 2013-11-25
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Role of PET/ CT with 18F-fluorocholine in the staging of patients with intermediate/high risk prostate cancer. Phase III, randomized, open-label clinical trial
    Medical condition: Histologically proven prostate cancer with Gleason score =7 and PSA>=10ng/ml or Gleason score >=8 and any PSA level or cT2-T3 and any PSA level or any Gleason score and PSA>=20ng/ml and indication ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003386-22 Sponsor Protocol Number: PRX302-2-07 Start Date*: 2015-01-19
    Sponsor Name:Sophiris Bio Corp
    Full Title: A Single Centre, Open Label, Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 to Treat Men with Histologically Proven, Clinically Signific...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001746-34 Sponsor Protocol Number: 56021927PCR3011 Start Date*: 2019-04-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
    Medical condition: High-risk localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002772-17 Sponsor Protocol Number: 22043-30041 Start Date*: 2009-06-22
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Immediate or early salvage post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment versus immediate or early salvage post-operative external radiotherapy alon...
    Medical condition: Prostatic carcinoma with pathological stage pT3a-b R0-1 N0M0 / pT2R1 N0M0, Gleason score 5-10
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036955 Prostatic carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000478-42 Sponsor Protocol Number: 008285QM Start Date*: 2013-02-18
    Sponsor Name:Queen Mary, University of London
    Full Title: NEPTUNE: A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer
    Medical condition: High or Intermediate Risk, Untreated, Clinically Localised Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002371-33 Sponsor Protocol Number: FS05-01 Start Date*: 2006-01-02
    Sponsor Name:Urologische Partnerschaft
    Full Title: Finasterid-unterstützte Diagnostik des Prostatakarzinoms bei Patienten mit BPH
    Medical condition: Adenoma of the prostate, elevated serum-PSA value
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002276-37 Sponsor Protocol Number: AK-2017-PC-1 Start Date*: 2017-08-25
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET
    Full Title: Phase II trial: uPAR-PET/MR in patients with newly diagnosed prostate cancer; non-invasive characterization of tumor aggressiveness
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003165-15 Sponsor Protocol Number: FACBC-STAGING-2014 Start Date*: 2014-12-02
    Sponsor Name:AOU di Bologna Policlinico S.Orsola-Malpighi
    Full Title: 18F-FACBC PET/CT FOR STAGING HIGH RISK PROSTATE CANCER
    Medical condition: Patients affected by moderate to high risk primary prostate cancer who are scheduled for surgery with a planned, elective lymph node dissection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036946 Prostatic cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000899-15 Sponsor Protocol Number: EORTC-1531-ROG Start Date*: 2019-12-03
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Radiotherapy and 6-month androgen deprivation therapy with or without apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a phase III study
    Medical condition: Intermediate and Limited High Risk Localized Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001784-13 Sponsor Protocol Number: ISRCTN91422391 Start Date*: 2014-12-29
    Sponsor Name:Queen Mary University of London
    Full Title: PROVENT: A randomised, double blind, placebo controlled feasibility study to examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease progression in men on active surveill...
    Medical condition: Prostate cancer disease progression
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022037-29 Sponsor Protocol Number: AFU-GETUG 20/0310 Start Date*: 2011-01-31
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of r...
    Medical condition: PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Gender: Male
    Trial protocol: FR (Trial now transitioned) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001920-36 Sponsor Protocol Number: NIMAO/2018-01/JF-01 Start Date*: 2020-12-03
    Sponsor Name:CHU de NIMES
    Full Title: Phase II a study to evaluate the safety, tolerability, distribution and dose effect of neoadjuvant doxorubicin arterial embolization in patients with prostate cancer at high risk of recurrence befo...
    Medical condition: patients with high-risk prostate cancer with a Gleason score of 9-10 on biopsy,multimodal treatment radical prostatectomy validated in CPR, managed in Hospital of Nîmes.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007113 Cancer of prostate LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014446-28 Sponsor Protocol Number: JANUS Start Date*: 2009-12-03
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: A PHASE II TRANSLATIONAL STUDY INVESTIGATING THE BIOLOGICAL EFFECTS OF THE ZOLEDRONIC ACID AS NEOADJUVANT THERAPY ON INVASIVE PROSTATE CANCER
    Medical condition: invasive prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036917 Prostate cancer stage I LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018770-20 Sponsor Protocol Number: DC-005 Start Date*: 2010-05-21
    Sponsor Name:Oslo University Hospital
    Full Title: Phase I/II trial of vaccine therapy in curative resected prostate cancer patients using autologous dendritic cells loaded with mRNA from primary prostate cancer tissue, hTERT and surviving.
    Medical condition: Prostatic cancer patients who have received curative surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004489-32 Sponsor Protocol Number: CV-9104-007 Start Date*: 2014-03-05
    Sponsor Name:CureVac AG
    Full Title: An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer
    Medical condition: prostate carcinoma (intermediate and high risk)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000476-26 Sponsor Protocol Number: N14DAR Start Date*: 2020-07-13
    Sponsor Name:Netherlands Cancer Institute
    Full Title: Dynamics of Androgen Receptor genomics and transcriptomics after neoadjuvant androgen ablation (DARANA)
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036920 Prostate cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036911 Prostate cancer recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036912 Prostate cancer stage 0 PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036917 Prostate cancer stage I PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036919 Prostate cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036918 Prostate cancer stage II PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 19 12:38:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA